ArticleBMC gastroenterology2026
Direct bilirubin was superior to total bilirubin in predicting the long-term outcomes of patients with primary biliary cholangitis.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND &
aimsTotal bilirubin (TB) has been regarded as a key prognostic factor for patients with primary biliary cholangitis (PBC), yet the prognostic significance of direct bilirubin (DB) is unclear. This study aimed to investigate the role of DB in predicting outcomes in patients with PBC.
methodsWe retrospectively reviewed the medical records of patients with PBC, and collected the follow-up data on liver biochemistry and clinical outcomes including decompensation, hepatocellular carcinoma, liver transplantation (LT), and liver-related deaths through regular outpatient visits and phone interviews.
resultsA total of 553 patients with PBC were enrolled and grouped by TB and DB after 12 months of ursodeoxycholic acid treatment (TB12 and DB12) : Group 1 (elevated TB12 and DB12, n = 145), Group 2 (elevated TB12 and normal DB12, n = 88), and Group 3 (normal TB12 and DB12, n = 308). After a median follow-up of 5.42 years, 63 patients (11.4%) developed LT or liver-related deaths. Patients in Group 2 exhibited comparable transplant-free survival rates and hepatic events incidence to those in Group 3, yet demonstrated significantly better transplant-free survival rates and lower hepatic events incidence than Group 1(both p < 0.001). Multivariate Cox analyses identified DB12, rather than TB or TB12, as an independent predictor of long-term outcomes. Finally, patients with normal DB12 experienced improved survival compared to those with elevated DB12, irrespective of ALP levels.
conclusionDB is a superior predictor of long-term outcomes than TB in PBC patients, attaining normal DB and ALP levels are associated with lower risk for LT or liver-related death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.